MYC and hepatocellular carcinoma: (Ponzielli et al., 2005) Accordingly, a therapeutic, DCR-MYC, a synthetic double-stranded RNA in a stable lipid particle suspension directed against MYC, has been developed and its intravenous infusion in solid and hepatocellular carcinoma patients showed good tolerability and encouraging early clinical and metabolic responses.